Skip to main content
Journal cover image

Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry.

Publication ,  Journal Article
Kontos, MC; de Lemos, JA; Ou, F-S; Wiviott, SD; Foody, JM; Newby, LK; Chen, A; Roe, MT
Published in: Am Heart J
November 2010

BACKGROUND: Despite the 2000 and 2007 redefinition of myocardial infarction (MI), patients who are troponin (Tn) positive ([+]) but MB negative ([-]) may not be considered to have MI, particularly in the absence of known coronary disease (prior MI or revascularization; coronary artery disease [CAD]). How this affects treatment and outcomes has not been well described. METHODS: Direct arrival patients with non-ST elevation MI (NSTEMI) enrolled in the American College of Cardiology NCDR ACTION-GWTG Registry were included. Patients missing marker data who were Tn (-) and had CAD were excluded. Troponin (+) patients were categorized as MB (+) (n = 11,563) or MB (-) (n = 4,501). Treatments and in-hospital outcomes were compared between the 2 groups using logistic regression. RESULTS: Of the 16,064 NSTEMI patients, 28% were MB (-). The MB (-) patients were older (median age 68 vs 65 years) and had more comorbidities (hypertension 71% vs 66%, diabetes 31% vs 27%, heart failure 22% vs 19%; all Ps < .01). After adjusting for baseline characteristics, MB (-) patients were significantly less likely to receive clopidogrel, antithrombins, glycoprotein IIb/IIIa antagonists, or angiography (all Ps < .001). In-hospital mortality was lower in MB (-) patients (3.8% vs 4.9%, P < .01), which remained significant after adjusting for baseline variables (odds ratio 0, 69, 95% CI 0.6-0.9, P = .002). CONCLUSIONS: Patients without known CAD who have NSTEMI and are MB (-) have a higher risk profile but are less likely to receive guideline-recommended acute pharmacologic treatment than those who are MB (+). Given the relatively high mortality in this group, increased emphasis on improving quality of care in Tn (+)/MB (-) patients is warranted.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2010

Volume

160

Issue

5

Start / End Page

819 / 825

Location

United States

Related Subject Headings

  • United States
  • Troponin
  • Ticlopidine
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Prognosis
  • Practice Guidelines as Topic
  • Platelet Aggregation Inhibitors
  • Myocardial Revascularization
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kontos, Michael C., James A. de Lemos, Fang-Shu Ou, Stephan D. Wiviott, Joanne M. Foody, L Kristin Newby, Anita Chen, and Matthew T. Roe. “Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry.Am Heart J 160, no. 5 (November 2010): 819–25. https://doi.org/10.1016/j.ahj.2010.07.022.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2010

Volume

160

Issue

5

Start / End Page

819 / 825

Location

United States

Related Subject Headings

  • United States
  • Troponin
  • Ticlopidine
  • Risk Factors
  • Retrospective Studies
  • Registries
  • Prognosis
  • Practice Guidelines as Topic
  • Platelet Aggregation Inhibitors
  • Myocardial Revascularization